High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Q2 13F filings show that billionaire Ken Fisher’s Fisher Asset Management opened new positions in CRISPR Therapeutics (NASDAQ: CRSP) and Coinbase Global (NASDAQ: COIN). Fisher’s fund bought 77,960 CRISPR Therapeutics shares valued at about $4.25 million as of June 30. The firm also purchased 9,714 Coinbase shares valued at about $1.42 million. Both stocks were […]
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Both companies are approaching milestones that could light a fire under their stocks.
We'll know a little more about the company's prospects by the end of the year.
Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CEO Samarth Kulkarni said the second quarter showed strong progress and that the company enters the second half “well positioned, with a number of important milestones ahead across our pipeline.”
The next six months may be decisive for the biotech.
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company's innovative qualities may pay rich dividends down the road.
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.
The fresh FDA approval allows the use of the cell therapy in patients as young as two years old with sickle cell disease (SCD) who have recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT).
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.
They have at least one thing in common: An exciting pipeline.
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 27, research firm Citizens reiterated a Market Perform rating and a $60 price target on CRISPR Therapeutics AG (NASDAQ:CRSP). The stance comes on the heels of the company maintaining a positive view of in vivo editing […]
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
The biotech's innovative platform could pay off.
Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: what are you actually paying for compared with what the business might be worth? Over the last week the stock return is 0.6%, over the last month it is 5.8%, and over the last year it is 58.0%, while the year-to-date return is a 2.6% decline and the three- and five-year returns are 17.4% and 49.4% declines respectively, which may catch the eye of both momentum fans and...
Vertex tops Q1 estimates as revenues climb 8% on strong CF drug demand and new product gains. Its pipeline has advanced and its 2026 guidance reaffirmed.
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
